1. Home
  2. DMRC vs IMUX Comparison

DMRC vs IMUX Comparison

Compare DMRC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$14.69

Market Cap

170.6M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$15.06

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
IMUX
Founded
2008
2016
Country
United States
United States
Employees
N/A
66
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.6M
152.6M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
DMRC
IMUX
Price
$14.69
$15.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$10.00
$36.00
AVG Volume (30 Days)
235.0K
255.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
18.58
38.00
EPS
N/A
N/A
Revenue
$25,213,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.69
N/A
52 Week Low
$4.07
$0.51
52 Week High
$15.24
$15.40

Technical Indicators

Market Signals
Indicator
DMRC
IMUX
Relative Strength Index (RSI) 75.43 83.06
Support Level $7.31 $0.74
Resistance Level N/A N/A
Average True Range (ATR) 1.46 1.18
MACD 0.42 -0.03
Stochastic Oscillator 92.67 84.29

Price Performance

Historical Comparison
DMRC
IMUX

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: